Contra-indicated in patients with severe hepatic or renal impairment.
- TRADE NAMES: Rapaflo (Watson); Urief (Kissei)
- INDICATIONS: Benign prostatic hyperplasia
- CLASS: Adrenergic alpha-receptor antagonist
- HALF-LIFE: 4.7–6 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alpha blockers, Antihypertensives, Atorvastatin, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Diltiazem, Erythromycin, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Ritonavir, Stong CYP3A4 inhibitors, Telithromycin, Vasodilators, Verapamil, Voriconazole - PREGNANCY: Not indicated for use in women
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
